XL388

XL388

CAT N°: 20237
Price:

From 182.00 154.70

XL388 is an orally bioavailable and ATP-competitive inhibitor of mammalian target of rapamycin (mTOR; IC50 = 9.9 nM).{42465} It is selective for mTOR over a panel of more than 140 kinases, including various PI3Ks (IC50s = >3,000 nM). It inhibits mTOR complex 1 (mTORC1) and mTORC2 in vitro (IC50s = 8 and 166 nM, respectively).{42466} XL388 induces cytotoxicity in MG-63, U2OS, and Saos-2 osteosarcoma and 786-0 kidney cancer cells and increases apoptosis in 786-0 and MG-63 cells in a concentration-dependent manner.{31720,42467} It also induces cell cycle arrest at the G1 phase and increases autophagy in MG-63 cells.{31720} XL388 (50 and 100 mg/kg) reduces tumor growth in an MCF-7 breast cancer mouse xenograft model and inhibits phosphorylation of the mTORC1 and mTORC2 substrates p70S6K, S6, 4E-BP1, and Akt in MCF-7 and PC-3 xenograft tumors when administered at a dose of 100 mg/kg.{42465} XL388 (20 mg/kg) also reduces tumor growth in U2OS and 786-0 mouse xenograft models.{31720,42467}

Territorial Availability: Available through Bertin Technologies only in France

  • Synonyms
    • [7-(6-amino-3-pyridinyl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl][3-fluoro-2-methyl-4-(methylsulfonyl)phenyl]-methanone
  • Correlated keywords
    • 1777807-51-8 XL-388 mTORC-1 2 MG63 U2-OS Saos2 MCF7 PC3 p70S6-K S-6 4EBP1
  • Product Overview:
    XL388 is an orally bioavailable and ATP-competitive inhibitor of mammalian target of rapamycin (mTOR; IC50 = 9.9 nM).{42465} It is selective for mTOR over a panel of more than 140 kinases, including various PI3Ks (IC50s = >3,000 nM). It inhibits mTOR complex 1 (mTORC1) and mTORC2 in vitro (IC50s = 8 and 166 nM, respectively).{42466} XL388 induces cytotoxicity in MG-63, U2OS, and Saos-2 osteosarcoma and 786-0 kidney cancer cells and increases apoptosis in 786-0 and MG-63 cells in a concentration-dependent manner.{31720,42467} It also induces cell cycle arrest at the G1 phase and increases autophagy in MG-63 cells.{31720} XL388 (50 and 100 mg/kg) reduces tumor growth in an MCF-7 breast cancer mouse xenograft model and inhibits phosphorylation of the mTORC1 and mTORC2 substrates p70S6K, S6, 4E-BP1, and Akt in MCF-7 and PC-3 xenograft tumors when administered at a dose of 100 mg/kg.{42465} XL388 (20 mg/kg) also reduces tumor growth in U2OS and 786-0 mouse xenograft models.{31720,42467}

We also advise you